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Precision medicine requires an understanding of cancer genes and mutational processes, as well as an
appreciation of the extent to which these are found heterogeneously in cancer cells during tumor evolution.
Here, we explore the processes shaping the cancer genome, placing these within the context of tumor
evolution and their impact on intratumor heterogeneity and drug development. We review evidence for con-
straints and contingencies to tumor evolution and highlight the clinical implications of diversity within tumors.
We outline the limitations of genome-driven targeted therapies and explore future strategies, including
immune and adaptive approaches, to address this therapeutic challenge.Given the size of the human diploid genome (6 billion base
pairs), even without an elevated mutation rate, the potential for
the acquisition of mutations over the course of a human lifetime
is vast (Lynch, 2010). Tumors sequenced at the exome level have
been found to harbor anything from merely one or two to thou-
sands of somatic aberrations, ranging from base-pair substitu-
tions to whole-genome doublings.
Tumors accumulate somatic aberrations through an evolu-
tionary process (Nowell, 1976). While the majority of these aber-
rations are likely to be passenger events that do not provide any
selective benefit to the cancer cell, a small subset will represent
cancer driver events, conferring a selective advantage (Kandoth
et al., 2013; Lawrence et al., 2014). Accumulating evidence sug-
gests that not every mutation, whether driver or passenger, will
be found in every cancer cell within a tumor (see reviews Swan-
ton, 2012; Yates and Campbell, 2012). While the types and dis-
tribution of mutations across the genome in a cancer cell can be
used to decipher the mutational processes that have been
active during its evolutionary history (Helleday et al., 2014),
the extent of heterogeneity and its dynamics over time can
reveal a tumor’s life history (Burrell et al., 2013a; Yates and
Campbell, 2012).
The heterogeneity observed within tumors and the myriad of
genome instability processes that shape tumor evolution over
space and time have important clinical implications and may
reflect the mismatch between cost and benefit of some anti-
cancer therapies (Fojo et al., 2014). For instance, between
2002 and 2012, of 71 anticancer drugs approved by the Food
and Drug Administration, including 52 targeted medicines, the
median overall survival benefit was 2.1months, balanced against
an estimated $10,000 per month on therapy at a cost of $2.7
million per life year saved (Kantarjian and Zwelling, 2013). Tar-
geted therapies will likely only have maximal efficacy when tar-
geting somatic events present in all cancer cells and may be
complicated by evidence that the number of cancer drivers in
advanced tumors may be substantial (Gerlinger et al., 2014).
Moreover, increasing evidence is emerging for the presence of
polygenic drug-resistance mechanisms in subclones prior tothe initiation of therapy (Bozic et al., 2013) and that low-frequency
subclones can support the growth of the dominant clone. Future
drug development strategies must therefore take into account
clonal heterogeneity, as well as evidence that subclones can
compete and synergize for growth in a symbiotic manner.
In this review, we explore the processes shaping the cancer
genome and place these in the context of intratumor heteroge-
neity. We review the extent to which rules for tumor evolution,
which may guide precision medicine, can be deciphered and
outline the clinical implications associated with diversity within
tumors. Finally, we explore strategies that could be adopted to
help address this therapeutic challenge.
Biological Basis of Intratumor Heterogeneity and
Cancer Evolution
Genomic Instability and Endogenous and Exogenous
Mutational Processes
Genome instability processes result in an elevated rate of so-
matic aberrations, ranging from point mutations to chromosomal
and whole-genome doublings. This instability can contribute to
intratumor heterogeneity by providing a pool of mutations upon
which selection can act in a given microenvironmental context
(Burrell et al., 2013a). Thus, an understanding of genome insta-
bility processes is required to understand a biological basis for
tumor heterogeneity.
The characteristic mutations associated with a particular
genome instability process can be considered a ‘‘mutational
signature,’’ reflecting the imprint of the type of DNA damage
that has occurred. Such mutational signatures may exist at
both the nucleotide and chromosomal level simultaneously.
For example, non-small-cell lung tumors (NSCLCs) from heavy
cigarette smokers display a preponderance of C > A transver-
sions and significantly more copy number gains and mutations
compared with nonsmokers (Govindan et al., 2012; Huang
et al., 2011; Pleasance et al., 2010), while colorectal cancers
with endogenous mismatch repair deficiency exhibit an enrich-
ment of C > T transitions, particularly at CpG sites, and generally
show low levels of chromosomal alterations.Cancer Cell 27, January 12, 2015 ª2015 Elsevier Inc. 15
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A B Figure 1. Endogenous and Exogenous
Mutational Processes Alter the Evolutionary
Trajectory of a Tumor
(A) An age-related mutational process operates
throughout the evolution of a lung tumor. A
smoking-induced C > A mutation in TP53
(p.R158L) leads to the outgrowth of a major tumor
clone. Later in tumor evolution, APOBEC-medi-
ated mutagenesis results in a mutation to PIK3CA
(p.E545K), which leads to a subclonal expansion.
(B) The evolution a glioblastoma tumor that has
undergone treatment with Temozolomide (TMZ).
Notably, TMZ leads to mutations in CDKN2A and
RB1 in separate subclones, both of which lead to
subclonal expansions.
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Nucleotide Level
Recently, mathematical frameworks have been developed to
quantify the number and contributions of mutational signatures
operating within cancers at the single-nucleotide level (Alexan-
drov et al., 2013; Fischer et al., 2013). Application of nonnegative
matrix factorization to more than 7,000 tumors from over 30 can-
cer types identified 20 distinct mutational signatures (Alexandrov
et al., 2013). The plethora of mutational signatures identified re-
flects the diverse array of endogenous and exogenous genome
instability processes that can operate in cancers during evolu-
tion. Intriguingly, in many cases, the underlying etiology of these
mutational signatures remains unknown (Helleday et al., 2014).
In the majority of cancer samples analyzed, at least two muta-
tional processes were identified, consistent with an elevatedmu-
tation rate in most cancers (Alexandrov et al., 2013). The most
widespread mutational signature, identified in 25 cancer types,
was characterized by C > T transitions at CpG sites, probably
reflecting deamination of 5-methylcytosines at CpG sites. This
signature correlated with patient age (Alexandrov et al., 2013),
consistent with a large proportion of these mutations having
been acquired prior to tumorigenesis.
Another pervasivemutational signature, identified in 15 cancer
types, has been linked to the endogenous activity of apolipo-
protein B mRNA editing enzyme, catalytic polypeptide-like
(APOBEC) cytidine deaminases and is characterized by C > T
and C > Gmutations at TpC sites (Alexandrov et al., 2013; Burns
et al., 2013; Roberts et al., 2013). APOBEC-mediated mutagen-
esis can also be linked to the acquisition of driver mutations,
emphasizing the likely importance of this mutational process in
the shaping of the evolution of the cancer genome (Figure 1A).
A large proportion of PIK3CA helical domain mutations in human
papillomavirus-driven tumors display an APOBEC motif (Hen-
derson et al., 2014). Moreover, in NSCLC, our group found evi-
dence that while early mutations were dominated by smoking
induced C > A transversions, APOBEC-mediated mutagenesis16 Cancer Cell 27, January 12, 2015 ª2015 Elsevier Inc.was the dominant mutational force later
in tumor evolution, conceivably providing
a fertile substrate for tumor adaptation to
environmental and targeted, cytotoxic, or
radiation therapy-induced selection pres-
sures (de Bruin et al., 2014). Consistent
with the importance of this mutational
process later in NSCLC evolution, over15% subclonal mutations in driver genes, including PIK3CA,
TGFBR1, and PTPRD, were found within an APOBEC context.
Additionally, geographically distinct regions of the same tumor
displayed different levels of APOBEC-mediated mutagenesis
(de Bruin et al., 2014), suggesting drivers of diversity themselves
can be both spatially heterogeneous and alter in dominance over
time.
Therapy may also act as an exogenous source of genome
instability (Cahill et al., 2007; Ding et al., 2012; Hunter et al.,
2006; Johnson et al., 2014). Ding et al. (2012) studied the clonal
evolution of primary and relapsed acute myeloid leukemia (AML)
and found an increase in transversions following cytotoxic ther-
apy at relapse (46%) compared with mutations prior to therapy
(30.7%). Consistent with this, in C. elegans, cisplatin treatment
has been found to lead to a striking, dose-dependent increase
in base substitutions—predominantly C > A transversions—as
well as an elevated rate of dinucleotide substitutions, indels,
and structural variants (Meier et al., 2014). Temozolomide treat-
ment has also been found to leave an imprint in the cancer
genome in the form of an elevated rate of C > T transitions—pri-
marily at CpC and CpT sites (Alexandrov et al., 2013; Johnson
et al., 2014). Costello’s laboratory performed a comparison of
the genomic landscape of gliomas at initial diagnosis and recur-
rence and found that 6 of 10 tumors that recurred as glioblas-
tomas, a high-grade tumor with worse prognosis, displayed
evidence of hypermutation—exhibiting 7–450 times the muta-
tional load per megabase compared with primary gliomas.
Furthermore, all hypermutant tumors were treated with temozo-
lomide, and many temozolomide-induced mutations were found
in driver genes, including RB1 and CDKN2A (Johnson et al.,
2014) (Figure 1B). In these examples, therapy was not acting
merely as an exogenous source of mutations but also as a selec-
tion barrier, shaping the evolutionary trajectory of a tumor and its
progression to a more aggressive phase.
Consistent with therapy acting as a selection barrier, in
NSCLC, chemotherapy was found to reduce EGFR mutation
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clones with oxaliplatin resulted in outgrowth of previously
dormant, resting clones (Kreso et al., 2013). In this case, chemo-
therapy did not act as an exogenous source of mutations, as the
effect was independent of acquired genetic mutations, high-
lighting the importance of nongenetic mechanisms in generating
diversity within tumors. In support of this, phenotypic behavior
and fate of identical daughter cancer cells can be vastly different
upon treatment despite identical genetic backgrounds (Gas-
coigne and Taylor, 2008). Interestingly, in AML, while morpho-
logical and phenotypic features as well as growth properties
were found to correlate with distinct genetically defined sub-
clones, the engraftment of AML cells in mice did not relate to
the genetically defined evolutionary hierarchy (Klco et al., 2014).
Genome Instability Processes at Copy Number Level
Genome instability processes and mutational signatures can
also be deciphered through copy number analysis. Homologous
recombination (HR) deficiency is thought to lead to a specific
copy number profile, resulting in allelic imbalance (Abkevich
et al., 2012; Birkbak et al., 2012; Popova et al., 2012). The clinical
importance of this HR signature is underscored by the observa-
tions that it predicts cisplatin sensitivity in vitro and response to
preoperative cisplatin treatment in patients with triple-negative
breast cancer (Birkbak et al., 2012). Copy number aberrations
can also be used to quantify the level of chromosomal instability
(CIN) (Birkbak et al., 2011), a driving force of intercellular genetic
heterogeneity (Lengauer et al., 1997). In colorectal cancer, aneu-
ploid tumors frequently harbor loss of chromosome 18q. We
have found that loss of three ‘‘CIN-suppressor genes’’ encoded
on 18q is an early event in tumor evolution occurring at the onset
of aneuploidy. Depletion of these three genes in vitro initiates
replication stress and generation of structural CIN and numerical
CIN defined by centromeric fluorescence in situ hybridization,
resulting in intercellular heterogeneity (Burrell et al., 2013b).
Chromothripsis, a single event that results in tens to thou-
sands of chromosomal rearrangements localized to one or a
few chromosomes (Stephens et al., 2011), is thought to occur
in 5% of cancers and can be detected using allele-specific
copy number data (Zack et al., 2013). The event likely results
from distinct chromosomes or chromosomal regions becoming
fragmented into multiple segments and then being pieced
back together inaccurately through DNA repair mechanisms.
Finally, at the genome level, whole-genome doublings have
been documented to occur frequently across a range of cancers
and can be estimated from allele-specific copy number data
(Carter et al., 2012; Dewhurst et al., 2014; Zack et al., 2013).
Although the underlying causes and tolerance mechanisms of
genome doubling remain unclear, it has been postulated to
represent a macroevolutionary leap in the development of tu-
mors. This is supported by observations that genome doubling
is associated with accelerated cancer genome evolution and
elevated levels of chromosomal alterations (Dewhurst et al.,
2014; Zack et al., 2013).
Contingency, Convergence, and Rules of Evolution
While analysis of individual cancer genomes can shed light on
the mutational processes that have been operative during tumor
evolution, from a therapeutic perspective, there is a need to
determine whether trends and patterns in the evolution of cancergenomes through space and time can be deciphered. This issue
is reminiscent of the long-standing and contentious debate on
whether macroevolutionary trends and rules exist and Gould’s
famous assertion that if the tape of life were rewound and played
again a different evolutionary outcome would result (Gould,
1989). Such a notion does not imply evolution is random; rather,
the final outcome is contingent upon the sequence of antecedent
steps (Gould, 1989). Convergence, on the hand, has been
championed as an opposing theory to contingency, suggesting
that constraints to evolution may lead to a limited set of poten-
tially repeated outcomes. Studies exploring evolutionary his-
tories of tumors and epistatic interactions have begun to shed
light on the interplay between contingency and convergence in
cancer development and the possibility of an evolutionary rule-
book dictating cancer evolutionary routes (Ashworth et al.,
2011).
Modes of Tumor Evolution and Cooperation between
Tumor Subclones
Longitudinal (Johnson et al., 2014; Mullighan et al., 2008; Shah
et al., 2009), spatial (Aerts et al., 2014; Bashashati et al., 2013;
Campbell et al., 2010; Gerlinger et al., 2012, 2014; Haffner
et al., 2013; Navin et al., 2010, 2011; Thirlwell et al., 2010; Ya-
chida et al., 2010), and in-depth mapping of single tumor sam-
ples (Anderson et al., 2011; Nik-Zainal et al., 2012a, 2012b;
Shah et al., 2012) are increasingly revealing a process of
branched tumor evolution acrossmultiple cancer types (Figure 2;
for reviews, see Navin, 2014; Swanton, 2012; Yates and Camp-
bell, 2012).
Recent studies have also shed light on the extent to which
genetically distinct subclones interact during tumor evolution
(Calbo et al., 2011; Inda et al., 2010; Marusyk et al., 2014; Misale
et al., 2012). In glioblastoma, a low-frequency EGFRvIII subclone
was found to contribute to growth of the dominant clone through
paracrinemechanisms (Inda et al., 2010). Co-operation of clones
has also been documented in mouse Wnt-driven mammary tu-
mors (Cleary et al., 2014) and Drosophila, where distinct clones
bearing RASV12 and SCRIB loss of function mutations cooperate
to induce JNK signaling and activation of growth promoting cy-
tokines (Wu et al., 2010). Likewise, using a zebrafish melanoma
xenograft model, inherently invasive as well as poorly invasive
melanoma subpopulations can coinvade in a symbiotic manner,
without clonal selection or phenotype switching (Chapman et al.,
2014).
Conceivably, clonal cooperation applies to many aspects of
tumor growth and progression. Indeed, in a mouse model of
small-cell lung cancer, Berns and colleagues (Calbo et al.,
2011) demonstrated cross-talk between two histopathologically
distinct populations of neuroendocrine and mesenchymal cells
sharing the same genetic origin (Calbo et al., 2011). The neuroen-
docrine cells acquired metastatic potential when the two cellular
populations were engrafted together (Calbo et al., 2011). Relat-
edly, in colorectal cancer Alberto Bardelli’s group recently
demonstrated that low-frequency KRAS mutant subclones—
that are resistant to cetuximab—can support the survival of
KRAS WT, drug-sensitive subclones through the paracrine
release of transforming growth factor b and amphiregulin (Hobor
et al., 2014). Clonal cooperation may explain observed clonal
equilibrium in chronic lymphocytic leukemia (CLL), in which the
relative sizes of subclones were found to persist over severalCancer Cell 27, January 12, 2015 ª2015 Elsevier Inc. 17
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Figure 2. Modes of Tumor Evolution
(A) Linear evolution involves sequential accumu-
lation of mutations over time. As can be seen,
linear evolution can result in heterogeneity if a
subclone has failed to outcompete its pre-
decessors.
(B) Tumor subclones may evolve through a pro-
cess equivalent to allopatric speciation when
subclonal populations are geographically distinct
within a tumor.
(C) Clonal competition can occur between sub-
clonal populations, where distinct subclones
compete for growth advantages (equivalent to an
antagonistic relationship).
(D) Subclonal populations may cooperate, result-
ing in a symbiotic relationship.
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clonal cooperation can result in tumor collapse through clonal
interference; for example, if the non-cell-autonomous driver
subclone is outcompeted by a subclone with higher proliferative
potential that cannot survive independently (Marusyk et al.,
2014).
Taken together, these data suggest that tumors represent a
complex dynamic ecological system where heterogeneity is
not only a substrate for evolution, but can also promote, or
even be a requirement for, continued tumor development and
progression. It will be important to determine the extent to which
subclones compete and cooperate in different tumor types and
in individual cases. In NSCLC and clear cell renal cell carcinoma
(ccRCC), tumor subclones within the primary tumor appear
geographically distinct (de Bruin et al., 2014; Gerlinger et al.,
2014). These observations suggest a process equivalent to
allopatric speciation might be operating in these tumor types,
whereby subclones become geographically isolated, resulting
in genetically distinct subclones in different tumor regions
(Figure 2B). Nevertheless, evidence that subclones can compete
and synergize for growth suggests in certain cases that cancer
drug development strategies may have to adapt to identify and
target small populations of cells that support the growth and sur-
vival of neighboring cells in the tumor.
Temporal Dissection of Mutations and Epistatic
Interactions
From a clinical standpoint, if mutations in certain genes are al-
ways early events, these may be particularly appealing targets
for therapy (Table 1). In colorectal cancer, Fearon and Vogelstein
(1990) used the frequency of somatic events across independent
colorectal tumors at different stages of tumor development to
infer their likely temporal order. According to this model, there18 Cancer Cell 27, January 12, 2015 ª2015 Elsevier Inc.are two routes resulting in colorectal can-
cer, one through inactivation of APC and
the other through mismatch repair defi-
ciency. Such a model becomes more
complex when branched evolution is con-
sidered within tumors. In fact, heteroge-
neity itself can be used to infer the tempo-
ral sequence of somatic events in cancer.
Clonal mutations, occurring on the trunk
of a tumor’s phylogenetic tree, are early
events, whereas subclonal events, occur-ring on the branches, reflect later events (Campbell et al., 2010;
Gerlinger et al., 2012; Greaves and Maley, 2012; Landau et al.,
2013). In addition, computational methods have been developed
to elucidate the temporal acquisition of genomic events in can-
cers from cross-sectional mutation data (Attolini et al., 2010;
Beerenwinkel et al., 2014; Gerstung et al., 2011).
Multiregion sequencing of 10 ccRCCs has revealed that muta-
tions in von Hippel-Lindau gene (VHL), together with loss of chro-
mosome 3p, are obligatory early events in this cancer type
(Gerlinger et al., 2014). However, mutations in TP53, SETD2,
BAP1,PTEN,MTOR, andKDM5Cwereonly ever found tobe sub-
clonal, suggesting these are later events in ccRCC evolution. In
contrast to ccRCC, in breast, ovarian, pancreatic, and esopha-
geal cancers, TP53 mutations have been found generally to be
early events (Bashashati et al., 2013; Nik-Zainal et al., 2012b;
Shah et al., 2012; Weaver et al., 2014; Yachida et al., 2010).
Indeed,TP53was found tobeoneof theonlymutations that could
predict progression from Barrett’s esophagus to esophageal
adenocarcinoma (Weaver et al., 2014). This implies that in many
cancers mutations in TP53may be one of the founder mutations,
while in other cancers TP53mutations may play a role in mainte-
nance and progression, occurring at the onset or after subclonal
diversification. In colorectal cancer, driver mutations in KRAS,
NRAS, and BRAFwere found to be concordant between primary
tumorandmetastasis, implying theseareoftenearly events (Bran-
non et al., 2014). In contrast, inmyelodysplastic syndrome (MDS),
it was found thatmutations inNRASwere among the latest events
while mutations in genes involved in splicing, such as U2AF1,
were often the earliest (Papaemmanuil et al., 2013).
In the context of multiple myeloma (MM), driver events such
asBRAFmutations can be clonal in some patients and subclonal
in others, where they can co-occur with RAS mutations,
Table 1. Summary of Truncal and Branched Driver Events across Cancer Types
Tumor Type Trunk Driversa Branch Drivers References
AML DNMT3A, TET2, t(15;17),
t(8;21), t(16;16), inv(16)
WT1, KRAS, NRAS, KIT Welch, 2014
Breast TP53, PIK3CA BRCA2 Martins et al., 2012; Nik-Zainal et al.,
2012a; Shah et al., 2012
CLL MYD88 SF3B1, TP53 Landau et al., 2013
Colorectalb KRAS, NRAS, BRAF TP53, PIK3CA Brannon et al., 2014; Vakiani et al., 2012
Ewing Sarcoma EWSR1-ETS fusion STAG2 Tirode et al., 2014
Follicular
lymphoma
BCl2-IGH (14;18), MLL2,
CREBBP, EZH2
MYD88, TNFAIP3, MYC, TP53 Okosun et al., 2014
Glioma IDH1 SMARCA4, BRAF, TP53, ATRX Johnson et al., 2014
MDS SF3B1, SRSF2, U2AF1, DNMT3A NRAS Papaemmanuil et al., 2013
Melanomac BRAF NRAS, MEK1 Van Allen et al., 2014
Myeloma IgH rearrangements KRAS, NRAS, BRAF, FAM46C Bolli et al., 2014; Lohr et al., 2014;
Melchor et al., 2014
NSCLC BRAF, NF1, TP53, EGFR HGF, MLL3 Chen et al., 2012; de Bruin et al., 2014;
Govindan et al., 2012
Esophageal
adenocarcinoma
TP53, SMAD4 MYO18B, TRIM58, CNTNAP5,
ABCB1, PCDH9, UNC13C,
SEMA5A, CCDC102B
Weaver et al., 2014
Ovarian TP53 PIK3CA, CTNNB1, NF1 Bashashati et al., 2013
Prostate ERG rearrangements, 21q22 deletion,
NKX3-1 deletion FOXP1, SPOP
PTEN, CDKN1B, AR amplification Baca et al., 2013; Haffner et al., 2013
Pancreatic KRAS, CDKN2A, TP53, SMAD4 OVCH1 Yachida and Iacobuzio-Donahue, 2013
Renal VHL, PBRM1*, 3p loss of
heterozygosity
SETD2, BAP1, KDM5C, MTOR,
TSC1, TSC2, TP53
Gerlinger et al., 2012, 2014
aGenes with an asterisk have also been found to be subclonal in multiregion samples.
bComparative sequencing analysis was used between matched primary and metastatic colorectal lesions to define potential branched status.
cBranched drivers defined in BRAF mutant melanoma.
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ation or maintenance and progression (Bolli et al., 2014; Lohr
et al., 2014). Similarly, in CLL, mutations in TP53 were found to
be subclonal in approximately 50% of cases and only mutations
toMYD88 were found to be almost always clonal (Landau et al.,
2013). Evidence of subclonal driver mutations may complicate
targeted therapy approaches (see below).
Epistatic interactions, whereby the action of each gene is
dependent on its genetic background, may play a key role in
dictating the order in which mutations are acquired (Figure 3A).
For example, in the presence of WT p53, loss of BRCA1 or
BRCA2 results in acute cell-cycle arrest; thus, it is likely that
TP53mutations usually occur before BRCA loss of function (Ash-
worth et al., 2011). This scenario is supported by studies in
BRCA1-associated breast tumors where loss of the remaining
WT BRCA1 often occurred after loss of TP53 (Martins et al.,
2012). Moreover, the early somatic alterations were found to in-
fluence the evolutionary trajectory of a tumor, with themajority of
luminal breast tumors displaying early mutations to TP53, while
loss of PTEN was observed as the first event in basal-like breast
cancers. Similarly, in MDS, the type of early driver mutations can
dictate the future trajectories of disease evolution (Papaemma-
nuil et al., 2013). These results suggest that certain mutations
may result in a form of genetic canalization in which a tumor is
forced down a particular evolutionary path in which subsequent
evolutionary opportunities are restricted.Parallel Evolution
In evolutionary biology, parallel evolution is defined as the de-
velopment of similar traits in related but distinct species, de-
scending from the same ancestor. Despite striking diversity
within individual tumors, parallel evolution occurring in geneti-
cally distinct subclones is an emerging theme across multiple
malignancies (Figure 3).
In acute lymphoblastic leukemia (ALL), deletions inETV6,PAX5,
and CDKN2A were found to occur independently in distinct sub-
clones from the same tumor (Anderson et al., 2011). Similarly, in
metastatic pancreatic cancer, distinct metastatic sites have
been found to harbor independent out of frame deletions of exon
6 of PARK2 (Campbell et al., 2010). In ccRCC, we found evidence
of parallel evolution in six of ten tumors analyzed, with distinct so-
matic events in different tumor regions affecting the same gene
(e.g., SETD2, KDM5C), pathway (PIK3CA, PTEN, MTOR) or pro-
tein complex (PBRM1, ARID1A, and SMARCA4) (Gerlinger et al.,
2014).Moreover, by investigating four tumors occurring in the kid-
neys of a young patient with Von Hippel Lindau syndrome, we
explored both contingencies and convergence during tumor evo-
lution. Each tumorwas found tohavean independent clonal origin,
with distinct chromosome 3p LOH events, resulting in biallelic
inactivationofVHL. However, despite distinct tertiarydriver events
in every tumor, conceivably contingent on the prior 3p LOH event,
convergence for functional activation of the mTOR pathway was
observed in all four tumors (Fisher et al., 2014).Cancer Cell 27, January 12, 2015 ª2015 Elsevier Inc. 19
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A B Figure 3. Epistatic Interactions and Parallel
Evolution
(A) The order of mutational acquisition can influ-
ence the evolution of a tumor. If gene X is mutated
before gene Y this results in a subclonal expan-
sion, whereas if gene Y is mutated before gene X
this results in cell death.
(B) Two subclonal populations of tumor cells
independently acquire mutations to gene X, re-
sulting in parallel evolution.
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PerspectiveIn recurrent glioma, mutations in ATRX and TP53 distinct from
mutations in the same genes identified in the primary tumor have
been observed (Johnson et al., 2014). Similarly, in glioblastoma,
through a single cell sequencing approach (leveraging data from
bulk genomic sequencing), Francis et al. (2014) demonstrated
parallel evolution of somatic alterations following EGFR amplifi-
cation, involving distinct EGFRvII, EGFRvII-ext., EGFR (del25-
28), and EGFR (del25-26) alterations in different cells within the
same tumor. Distinct mutations in KMT2D, TNFRSF14, and
CREBBP occurring independently in two patients with follicular
lymphoma and their paired transformed follicular lymphomas,
occurring later in the disease course, suggest critical depen-
dencies on mutational events in these genes for tumor mainte-
nance or progression (Okosun et al., 2014). Finally, in myeloma,
independent subclones within the same tumor driving RAS/
MAPK pathway activation through distinct RAS mutations have
been observed (Melchor et al., 2014).
Evidence for parallel evolution and recurrent patterns in the
temporal acquisition of mutations argues against viewing tumor
evolution as a purely contingent process and emphasizes the
existence of constraints to tumor development. Further clonal
evolution studies in thousands of tumors together with a deeper
understanding of the host microenvironment and germline may
allow the prediction of future evolutionary paths and herald
pre-emptive treatment strategies in contrast to current reactive
clinical approaches.
Clinical Implications of Intratumor Heterogeneity
Drivers, Heterogeneity, and Outcome
While it has long been established that CIN, resulting in cell-
to-cell genetic heterogeneity, is associated with poor prog-20 Cancer Cell 27, January 12, 2015 ª2015 Elsevier Inc.nosis across a wide range of cancers
(McGranahan et al., 2012), the relation-
ship between clonal heterogeneity and
outcome and the clinical significance
of subclonal driver mutations is only
beginning to be explored across can-
cers.
In CLL, the presence of subclonal
drivers was associated with a shorter
time to retreatment or death (Landau
et al., 2013), and in head-and-neck can-
cer, a measurement capturing the clonal
diversity—termed mutant allele tumor
heterogeneity—was found to correlate
with poor prognosis (Mroz and Rocco,
2013). In 11 early-stage NSCLCs, pri-
mary tumors from three patients withrelapsed disease had significantly larger subclonal fractions
than tumors from patients with relapse free tumors (Zhang
et al., 2014). In MDS, the number of driver events was the key
determinant of outcome, regardless of their clonal status; i.e.,
the presence of a driver was more critical than whether it was
subclonal or clonal (Papaemmanuil et al., 2013). Interestingly,
in a series of 28 patients with MM, those with the highest cyto-
genetically defined clinical risk harbored disease that was most
dynamic during the course of treatment (Keats et al., 2012).
Likewise, in ccRCC, a poor prognosis ccB signature that re-
mains a significant prognostic indicator in multivariate analysis
defines tumors with multiple high-risk genetic alterations, po-
tentially catalyzed by CIN (Gulati et al., 2014). Similarly, an
exploration of glioblastoma tumors at the single-cell level
revealed that proneural tumors harboring more diverse tran-
scriptionally defined subtype repertoires were associated with
poorest outcome (Patel et al., 2014).
Taken together, these data suggest that the plasticity of the
cancer genome permits dynamic subclonal changes and the
gain and loss of distinct genetic aberrations during the disease
course. This plasticity may allow the tumor to adapt in the
presence of microenvironmental pressures (Melchor et al.,
2014). Although these studies hint at the clinical importance
of intratumor heterogeneity, there is a need to prospectively
explore the impact of plasticity and diversity within tumors
and the relevance of subclonal driver events to therapeutic
outcome. In NSCLC, a United Kingdom-based longitudinal
study, Tracking Non-small Cell Lung Cancer Evolution
Through Therapy (TRACERx http://clinicaltrials.gov/show/
NCT01888601), has been launched to assess this (Jamal-Han-
jani et al., 2014).
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Most drug development programs employing next-generation
sequencing as a stratification tool do not consider the clonal or
subclonal frequencies of a driver alteration, simply their pres-
ence or absence. Indeed, major targeted therapy strategies are
in progress targeting the PI3K signaling axis despite evidence
that somatic mutations in members of this pathway, including
PTEN, PIK3CA, and MTOR, are often or always subclonal in
ccRCC, ovarian, and prostate cancers (Table 1). The clinical
impact of driver variant allele frequency and the relative domi-
nance of subclones with actionable alterations are priority areas
for development within the context of clinical trial design.
Emerging patterns of the temporal acquisition of mutations
should further inform targeted therapy approaches. Until we
have a greater understanding of complex paracrine and non-
cell-autonomous interactions of cancer subclones, targeting a
clonally dominant, truncal driver may provide a more effective
drug development strategy than simply considering actionable
alterations as present or absent (Lohr et al., 2014; Yap et al.,
2012). The DARWIN trial (Deciphering Anti-tumor Response
With INtratumor Heterogeneity) (http://clinicaltrials.gov/show/
NCT02183883) aims to assess whether targeting a clonally
dominant driver event results in improved progression free sur-
vival outcomes relative to targeting the same driver event when
it is present subclonally. In addition, these studies will monitor
the subclonal dynamics through therapy and during the acquisi-
tion of drug resistance.
It is also important to consider the impact an emerging resis-
tant subclone might have on disease biology in the face of
continued drug exposure. In the majority of cases of BRAF
mutant melanoma, resistance to a BRAF inhibitor is mediated
by reactivation of the RAS-ERK signaling pathway, for example,
through a mutation to RAS. Marais and colleagues recently
demonstrated that continued BRAF inhibitor treatment in RAS
and BRAFmutant melanoma cells results in release of proteases
and a morphological switch that fosters tumor metastatic pro-
gression (Sanchez-Laorden et al., 2014). These data support
the contention that rather than therapy having no effect on the
behavior of drug resistant disease, in certain contexts, continued
therapy in the presence of a resistant subclone might accelerate
tumor progression. Likewise, evidence is emerging that in MM
use of BRAF inhibitors in BRAFWT or RASmutant clones results
in paradoxical activation of the RAS-ERK pathway (Lohr et al.,
2014).
These data raise caution when considering an actionable
somatic event as either present or absent and suggest future
drug development efforts will have to account for the clonal or
subclonal nature of driver events prior to targeted intervention.
Indeed, these complexities emphasize the continued need for
in-depth biological understanding of drug response within the
context of controlled clinical protocols. Ignoring the fact that
driver events may be heterogeneous and thereby their potential
deleterious impact in the face of therapeutic selection pressures,
risks undermining a central principle of bioethics in medicine—
‘‘first do no harm.’’
Mechanisms of resistance may be driven by the presence of
subclones barely detectable at presentation. Evidence in mela-
noma (Shi et al., 2014; Van Allen et al., 2014) and colorectal can-
cer (Diaz et al., 2012) suggests that resistance to therapy mayoccur through multiple somatic events simultaneously within
the same tumor. For example, following BRAF inhibitor therapy
in BRAF V600 mutant melanoma, individual tumors were found
to develop multiple resistance events, including NRAS and
MEK1mutations in one patient and two distinctNRASmutations
in another (Van Allen et al., 2014). Moreover, resistance to BRAF
inhibitors can occur through both mitogen-activated protein ki-
nase (MAPK) pathway-dependent and PI3K-AKT-dependent
mechanisms in the same patient simultaneously (Shi et al.,
2014; Turajlic et al., 2014). Similarly, in one patient with colorectal
cancer, through longitudinal tracking of cell free tumor DNA, Diaz
et al. (2012) documented four distinct KRASmutations emerging
during the acquisition of resistance to panitumumab therapy (tar-
geting EGFR).
Polygenic resistancemechanisms raise clear challengeswhen
considering sequential or combinatorial targeted therapy strate-
gies to forestall acquired resistance events in order to prolong
progression free survival times (Burrell and Swanton, 2014).
One potential approach in the face of intratumor heterogeneity
is to target multiple pathways simultaneously. The emergence
of KRAS mutant clones in colorectal cancer, which can be de-
tected noninvasively, suggest a strategy for delaying or attenu-
ating drug resistance may involve MEK inhibition as well as
anti-EGFR therapy (Misale et al., 2012). Indeed, it has been found
that blockade of MEK and EGFR in resistant tumor cells can lead
to prolonged ERK inhibition and impaired growth of multiple cell
line models (Misale et al., 2014). In the context of BRAF mutant
melanoma, upfront targeting of both MAPK and PI3K pathways
may act to limit the selection of drug-resistance mechanisms
and thereby ultimately prolong progression free survival times
(Shi et al., 2014), while combined BRAF and MEK inhibition re-
sults in improved progression-free survival (Flaherty et al.,
2012; Larkin et al., 2014).
However, the health economic and toxicity costs of combina-
torial targeted therapeutic strategies attenuating multiple clonal
or subclonal driver events, together with the need for evidence
of robust and clinically meaningful overall survival endpoints,
may limit the utility of these approaches. For this reason, it could
be argued that efforts to both understand the biology of cyto-
toxic response and to improve understanding of DNA damage
response pathways should be prioritized as a means to address
tumor heterogeneity. Observations that patients having tumors
with extreme CIN have improved prognosis compared with
those having tumors with intermediate levels of CIN support
the notion that manipulating genome instability pathways may
provide clinical benefits (Birkbak et al., 2011; Roylance et al.,
2011). The potential tractability of this approach is also sup-
ported by findings that elevating chromosome missegration
rates can be used as a strategy to kill tumor cells or limit tumor
development (Janssen et al., 2009; Weaver et al., 2007) and
that supplementing cells with nucleosides can reduce the fre-
quency of chromosomal segregation errors (Burrell et al.,
2013b).
Immunotherapy
Immunotherapy approaches that do not necessarily depend
on the clonality of a single target might overcome some of the
challenges of intratumor heterogeneity. Indeed, it has been
postulated that the same genome instability processes that
drive tumor heterogeneity may concomitantly provide fuel forCancer Cell 27, January 12, 2015 ª2015 Elsevier Inc. 21
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Specifically, each missense mutation has the potential to give
rise to a neoantigen that may be recognized by a patient’s own
immune system (Rajasagi et al., 2014). Such a scenario has
been given support by a recent meta-analysis of five cancer
types that found tumors with predicted neoantigens exhibited
an improved prognosis compared with tumors without neoanti-
gens (Brown et al., 2014) and emerging evidence that increased
benefit from immune checkpoint blockade is observed in NSCLC
from smokers, with a higher mutational load, compared with
nonsmokers (J.C. Soria et al., 2013, conference). The impact of
the neoantigenic repertoire contained within a tumor will also
be modulated by the inflammatory environment and whether im-
mune-regulatory checkpoints are permissive for T cell function
(Quezada and Peggs, 2013). The relevance of modulating the im-
mune system is underscored by the interest in trials that attempt
to remove the immunological brakes that block the induction of
anti-tumor responses, for example, through inhibition of CTLA-
4 or PDL-1 (Quezada and Peggs, 2013). Clinical studies such
as the TRACERx program may permit insights into the relation-
ship between tumor heterogeneity and immune modulation.
New Approaches to Clinical Management
Taking into account the evolutionary dynamics of tumor popula-
tions may provide an avenue for therapeutic strategies. For
instance, Gatenby’s adaptive therapy algorithm suggests focus
should be shifted from attempting to eliminate every cancer
cell, which may select for resistant untreatable subclones, to
controlling cancer growth by understanding and manipulating
the selection forces operating within a tumor.
In support of adaptive therapy, in a study of mice injected with
ovarian cancer cell lines, it was found that the adaptive therapy
algorithm—involving multiple dosages of carboplatin that are
lowered when growth is attenuated—resulted in lowered contin-
uous tumor burden compared with a standard treatment in-
volving high dosages of carboplatin (Gatenby et al., 2009).
Through adaptive therapy, it is thought tumor cells that are sen-
sitive to chemotherapy are maintained in the tumor population
rather than eradicated, preventing competitive release of drug
resistant, untreatable subclones.
In practice, however, an adaptive therapeutic strategy would
raise some difficulties, including a change of physician emphasis
from achieving maximal tumor control to maintaining disease
stability. Competitive release of drug resistant subclones follow-
ing eradication of the drug sensitive clone may be an additional
explanation for the lack of overall survival data, despite robust
progression free survival times, for many targeted therapeutics
(Fojo et al., 2014).
Quantifying Heterogeneity and Identifying
Subclonal Mutations
The relationships between diversity within tumors and clinical
outcome emphasize the need to develop sensitive clinical tools
to quantify intratumor heterogeneity and detect and monitor
the dynamics of subclonal events within tumors. Although a
plethora of bioinformatics approaches have been proposed for
quantifying heterogeneity from both single samples and multire-
gion samples (for a review, see Ding et al., 2014), deciphering the
clonal dominance of a driver event is not necessarily a trivial task.
Notably, in ccRCC and NSCLC, variant allele frequencies of
known driver events often appear clonally dominant within indi-22 Cancer Cell 27, January 12, 2015 ª2015 Elsevier Inc.vidual tumor regions but on further tumor sampling are revealed
as absent from other tumor regions, giving the illusion of clonal
dominance (de Bruin et al., 2014; Gerlinger et al., 2014). In addi-
tion, sampling bias due to intratumor heterogeneity is likely to
confound the development of companion diagnostics and the
implementation of clinically qualified biomarkers (Gulati et al.,
2014; Patel et al., 2014; Sottoriva et al., 2013).
It is important to note, too, that current informatics algorithms to
define driver genes are likely biased to detect clonally dominant
recurrent driver events. When one considers the possibility that
each tumor clademay harbor one ormore driver events, the num-
berof cancergenesoperating inanadvanced tumormay rise sub-
stantially beyond the current estimates of two to six per tumor
(Kandoth et al., 2013). Defining the number of driver events, their
subclonal nature, and their potential epistatic relationships will
likely requiremultiregion and longitudinal sequencingof individual
tumors and development of cell-free DNA (Diaz et al., 2012; For-
shew et al., 2012; Murtaza et al., 2013) and circulating tumor cell
technologies (Hodgkinsonetal., 2014; Lohret al., 2014) combined
with single-cell sequencing approaches (Hughes et al., 2014; Na-
vin, 2014).Moreover, these techniquesmaybe complemented by
imaging that can provide a noninvasive approach for quantifying
the extent of heterogeneity within tumors (Aerts et al., 2014).
Noninvasive approaches may also be used to track tumor pro-
gression during the disease course. In hematological tumors, it
has been shown that serial sampling of the same patients is
both feasible and informative (Ding et al., 2012; Mullighan et al.,
2008; Walter et al., 2012).
An understanding of a tumor’s evolutionary history and tumor
development also provides evidence highlighting the importance
of screening approaches to detect disease early while the tumor
bulk and diversity is low. In two NSCLC patients, we found evi-
dence that truncal driver mutations and genome doubling events
occurred within a smoking signature context, 20 years prior to
clinical detection (de Bruin et al., 2014). These data are consis-
tent with a prolonged tumor latency period after genome
doubling and before clinical detection in NSCLC, potentially
providing evidence underpinning the efficacy of screening ap-
proaches in this disease. On the other hand, it has been shown
that the majority of recurrently mutated genes in esophageal
adenocarcinoma are also mutated in never-dysplastic Barrett’s
esophagus, suggestingmany potential driver eventsmay be pre-
sent prior to tumorigenesis and in subclones that will never
become cancerous (Weaver et al., 2014). Similarly, pathogenic
mutations, implicated in hematological malignancies, have
been found in the blood of older individuals, without any evi-
dence of disease (Busque et al., 2012). Conceivably, macroevo-
lutionary events, such as genome doubling and large-scale chro-
mosomal rearrangements may often be required for cells to
make the leap from a benign to a malignant phase and therefore
may serve as useful markers for clinical risk prediction. Indeed,
esophageal adenocarcinomas are characterized by genome
doublings and have elevated genetic clonal diversity compared
with never-dysplastic Barett’s esophagus (Li et al., 2014; Maley
et al., 2006).
Tracing the origins of the ‘‘lethal subclone’’ may contribute to
screening approaches and efforts to stratify risk of recurrence
and, in due course, might complement classical histopatholog-
ical assessment. Haffner et al. (2013) found through longitudinal
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Perspectiveassessment of a prostate cancer over a 17-year disease course
that the lethal subclone that precipitated the visceral metastatic
disease derived from a low Gleason grade region of the primary
tumor. The challenge is to move from single case studies to
larger longitudinal cohorts in order to study the metastatic
process in more detail. Longitudinal studies such as TRACERx
combined with postmortem analyses to attempt to map
cancer subclones over time (Jamal-Hanjani et al., 2014) will be
needed to shed further light on the complex dynamics of tumor
evolution.
Conclusions
A primary goal of cancer genomics research has been to provide
a catalog of cancer genes and mutational processes that are
operative during cancer evolution (Alexandrov et al., 2013; Law-
rence et al., 2014). However, a crucial next step in realizing the
goals of precision medicine will be to complement this analysis
with knowledge of the extent to which key cancer genes and
mutational processes are heterogeneous within tumors and their
dynamics over time. Complementary to this will be the use of lon-
gitudinal cancer genomics data to inform upon the timing of so-
matic events in relation to the onset of specific forms of genomic
instability that might drive tumor diversity.
The study of tumor evolution over space and time has begun to
shed light on patterns and processes that dictate the evolution of
tumors. It is becoming increasingly apparent that tumors often
evolve through a process of branched evolution, and despite
substantial heterogeneity, parallel evolution is an emerging
theme acrossmalignancies. Studies are beginning to reveal rules
governing the temporal acquisition of mutations, with certain
driver events found to be predominantly truncal and others
occurring later in tumor evolution. These findings, coupled with
accumulating evidence thatmeasures of heterogeneity are asso-
ciated with poor prognosis, mandate the need for further studies
exploring the evolutionary history of tumors, their interactions
with the host stromal and immune environments, and the rules
dictating their progression.
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